Larazotide

The safety evidence for larazotide is limited and mixed, with most data coming from preclinical studies and a small number of clinical trials, some of which were terminated.

Known Side Effects

Evidence is thin on specific side effects in humans. The available clinical trials include:

• One Phase 2 safety and tolerability study in celiac disease patients (NCT00362856) - completed, but specific safety results not provided in the evidence
• One Phase 3 efficacy and safety study (NCT03569007) that was terminated, raising potential safety concerns
• An ongoing Phase 2 trial for long COVID treatment (NCT05747534)

Without access to the detailed results from these trials, the specific side effect profile in humans remains unclear.

Contraindications

No specific contraindications are established based on the available evidence. The safety data is insufficient to determine absolute contraindications.

Drug Interactions

No drug interactions are documented in the provided evidence. This represents a significant knowledge gap requiring further investigation.

Special Populations

The evidence includes some pediatric data, as one study examined larazotide treatment in "children with post-COVID multisystem inflammatory syndrome." However, safety data for special populations is extremely limited, including:

• Pregnant or breastfeeding women
• Elderly patients
• Patients with kidney or liver impairment
• Children (beyond the single post-COVID study)

Important Safety Considerations

The termination of a Phase 3 clinical trial (NCT03569007) for celiac disease is concerning and suggests potential safety or efficacy issues, though the specific reasons are not provided in the evidence.

Most safety data comes from animal studies examining conditions like eosinophilic enteritis, colitis, and fatty liver disease, which cannot be directly extrapolated to human safety.

Disclaimer

This information is for educational purposes only and should not replace professional medical advice. The safety profile of larazotide remains poorly characterized in humans. Patients considering this treatment should consult with their healthcare provider to discuss potential risks and benefits based on their individual medical situation.

The evidence for larazotide safety in humans is notably thin, and significant gaps exist in our understanding of its safety profile.